Carisma Therapeutics (NASDAQ:CARM) and ProPhase Labs (NASDAQ:PRPH) Head-To-Head Survey

Carisma Therapeutics (NASDAQ:CARM) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Profitability

This table compares Carisma Therapeutics and ProPhase Labs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-314.78%	-957.20%	-96.39%
ProPhase Labs	-217.64%	-62.92%	-30.22%

Risk & Volatility

Carisma Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.47, meaning that its share price is 147% less volatile than the S&P 500.

Institutional and Insider Ownership

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are owned by institutional investors. 12.6% of Carisma Therapeutics shares are owned by company insiders. Comparatively, 20.7% of ProPhase Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Carisma Therapeutics and ProPhase Labs, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	0	5	1	1	2.43
ProPhase Labs	0	0	0	0	0.00

Carisma Therapeutics currently has a consensus target price of $1.93, indicating a potential upside of 994.37%. Given Carisma Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Carisma Therapeutics is more favorable than ProPhase Labs.

Valuation and Earnings

This table compares Carisma Therapeutics and ProPhase Labs”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$19.63 million	0.37	-$86.88 million	($1.56)	-0.11
ProPhase Labs	$6.77 million	1.78	-$16.78 million	($1.26)	-0.23

ProPhase Labs has lower revenue, but higher earnings than Carisma Therapeutics. ProPhase Labs is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Carisma Therapeutics beats ProPhase Labs on 8 of the 15 factors compared between the two stocks.

About Carisma Therapeutics

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

About ProPhase Labs

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.